Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05643027 · ClinicalTrials.gov registry record · NA

A Novel Intervention for Patients With Cancer

A NA study of Cancer and Substance Use, sponsored by Dana-Farber Cancer Institute.

Recruiting
Registry status
NA
Development phase
40
Enrollment target
1
Study location

NCT05643027: Recruiting NA study of Cancer and Substance Use, sponsored by Dana-Farber Cancer Institute.

NCT05643027 is a NA study of Cancer and Substance Use that is actively recruiting participants, run by Dana-Farber Cancer Institute. The registered enrollment target is 40 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05643027, a NA study of Cancer and Substance Use, is actively recruiting participants, sponsored by Dana-Farber Cancer Institute.

RECRUITING
Registry status
NA
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

This research study is being done to develop an intervention for psychological symptoms that patients diagnosed with cancer may experience. Psychological symptoms may include thoughts, feelings, emotions, and memories The names of the study intervention and research activities involved in this study are/is: * Acceptance \& Commitment Therapy (ACT) for Cancer (involving 6 sessions with a licensed clinical psychologist) * Questionnaires * Post-study interview Consistent with the NIH Stage Model for Behavioral Intervention Development, the investigators have adapted an existing, empirically-validated intervention, Acceptance and Commitment Therapy (ACT), to address substance use disorder risk during cancer care. The core components of ACT are particularly well-suited to address the psychological processes underlying opioid misuse in individuals treated for cancer pain. The overarching aim is to assess the feasibility and acceptability of the intervention by conducting a randomized pilot trial of the revised intervention ("ACTION") for cancer patients on opioid therapy, and at risk for SUD.

Primary Outcome

enrollment rate of at least 60% and retention rate of at least 75%

Interventions

  • BEHAVIORAL Acceptance and Commitment Therapy

Study Locations (1)

Massachusetts

  • Dana Farber Cancer Institute - Boston

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2023-03-01
Est. Completion 2026-07-01
Phase NA
Dana-Farber Cancer Institute

781 total trials

What NCT05643027 shows while recruiting

NCT05643027 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower).

The record links to 3 conditions, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which Acceptance and Commitment Therapy is the first listed.

NCT05643027 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT05643027 about?

NCT05643027 is a clinical study titled "A Novel Intervention for Patients With Cancer". This research study is being done to develop an intervention for psychological symptoms that patients diagnosed with cancer may experience. Psychological symptoms may include thoughts, feelings, emotions, and memories The names of the study intervention and research activities involved in this stud...

What is the current status of trial NCT05643027?

This trial is currently recruiting. It is a NA study. The enrollment target is 40 participants. The study started on 2023-03-01. Estimated completion is 2026-07-01.

What conditions does trial NCT05643027 study?

This clinical trial studies the following conditions: Cancer, Substance Use, Psychological.

What interventions are being tested in trial NCT05643027?

The interventions under investigation include: Acceptance and Commitment Therapy (BEHAVIORAL).

Who is sponsoring clinical trial NCT05643027?

This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05643027 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05643027's enrollment target sits among peer trials

40 461st of 615 higher than 146 of 615 other Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01306019 · 40 participants · Phase 1

    Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

  • NCT01608152 · 40 participants

    Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

  • NCT01668082 · 40 participants · NA

    An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

  • NCT02015013 · 40 participants · Phase 2

    Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05643027, the US trial registry maintained by the National Library of Medicine. NCT05643027 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.